Patent intelligence · US
US 8093354
Process for preparing glycopeptide phosphonate derivatives
Process for preparing glycopeptide phosphonate derivatives
Patent details — US 8093354
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 10, 2012
- Expiration
- Jan 5, 2032
- Applicant
- Theravance, Inc.
- Claims
- 24
- CPC classes
- A61K, A61K38/00, A61P, A61P31/00
Quick answer
US 8093354 (Process for preparing glycopeptide phosphonate derivatives) is held by Theravance, Inc.. Status: granted. Granted Jan 10, 2012. Expires Jan 5, 2032 (5 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Theravance, Inc.
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61K, A61K38/00, A61P, A61P31/00, A61P31/04
More from Theravance, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12384761
Imidazolo indazole compounds as JAK inhibitors
granted -
US 12358931
3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor
granted -
US 12351561
Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
granted -
US 12285417
Methods for treating chronic obstructive pulmonary disease
granted -
US 12258316
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 12239638
Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
granted -
US 12172994
Pyrimidine compound as JAK kinase inhibitor
granted -
US 12122773
Crystalline hydrate of a JAK inhibitor compound
granted
Frequently asked questions
What is US patent 8093354?
US 8093354 (Process for preparing glycopeptide phosphonate derivatives) is held by Theravance, Inc.. Status: granted. Granted Jan 10, 2012. Expires Jan 5, 2032 (5 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8093354?
Theravance, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 635 pharmaceutical patents for this assignee.
When does US 8093354 expire?
Our index shows an expiration date of Jan 5, 2032 (5 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.